{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:58:32Z","timestamp":1753891112860,"version":"3.41.2"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2023.1232212","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:59:21Z","timestamp":1689641961000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Editorial: Proceedings and predictions in cardiac amyloidosis: unsolved mysteries and challenges for the future"],"prefix":"10.3389","volume":"10","author":[{"given":"Aldostefano","family":"Porcari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianfranco","family":"Sinagra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian D.","family":"Gillmore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1093\/cvr\/cvac119","article-title":"Transthyretin cardiac amyloidosis","volume":"118","author":"Porcari","year":"2023","journal-title":"Cardiovasc Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation."},{"key":"B3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1177\/2047487320920756","article-title":"Management of complications of cardiac amyloidosis: 10 questions and answers","volume":"28","author":"Aimo","year":"2020","journal-title":"Eur J Prev Cardiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1093\/eurjpc\/zwac237","article-title":"Comparison of different technetium-99m-labelled bone tracers for imaging cardiac amyloidosis","volume":"30","author":"Porcari","year":"2022","journal-title":"Eur J Prev Cardiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"749523","DOI":"10.3389\/fcvm.2021.749523","article-title":"Incidence and characterization of concealed cardiac amyloidosis among unselected elderly patients undergoing post-mortem examination","volume":"8","author":"Porcari","year":"2021","journal-title":"Front Cardiovasc Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jaccao.2022.08.009","article-title":"AL amyloidosis for cardiologists: awareness, diagnosis, and future prospects","volume":"4","author":"Wechalekar","year":"2022","journal-title":"JACC Cardio Oncology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/ejhf.2776","article-title":"Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy","volume":"25","author":"Porcari","year":"2023","journal-title":"Eur J Heart Fail."},{"key":"B9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41569-020-0334-7","article-title":"Diagnostic imaging of cardiac amyloidosis","volume":"17","author":"Martinez-Naharro","year":"2020","journal-title":"Nat Rev Cardiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1093\/eurheartj\/ehad139","article-title":"Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis","volume":"44","author":"Rauf","year":"2023","journal-title":"Eur Heart J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10741-022-10247-5","article-title":"Endomyocardial biopsy in the clinical context: current indications and challenging scenarios","volume":"28","author":"Porcari","year":"2022","journal-title":"Heart Fail Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/ejhf.2532","article-title":"Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies","volume":"24","author":"Aimo","year":"2022","journal-title":"Eur J Heart Fail."},{"key":"B14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/ejhf.1742","article-title":"Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies","volume":"22","author":"Milandri","year":"2020","journal-title":"Eur J Heart Fail."},{"key":"B15","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/ehf2.13606","article-title":"Prognostic significance of unexplained left ventricular hypertrophy in patients undergoing carpal tunnel surgery","volume":"9","author":"Porcari","year":"2022","journal-title":"ESC Hear Fail."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","article-title":"Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release","volume":"72","author":"Sperry","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1002\/ejhf.2646","article-title":"Sex differences among patients with transthyretin amyloid cardiomyopathy\u2014from diagnosis to prognosis","volume":"24","author":"Patel","year":"2022","journal-title":"Eur J Heart Fail."},{"key":"B18","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/ejhf.2824","article-title":"Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis","volume":"25","author":"Aimo","year":"2023","journal-title":"Eur J Heart Fail."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1002\/ejhf.2504","article-title":"Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey","volume":"24","author":"Merlo","year":"2022","journal-title":"Eur J Heart Fail."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1093\/eurjpc\/zwab127","article-title":"A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization\u2014the first insight from the AC-TIVE Study","volume":"29","author":"Merlo","year":"2022","journal-title":"Eur J Prev Cardiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1002\/ejhf.2606","article-title":"Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis","volume":"24","author":"Chacko","year":"2022","journal-title":"Eur J Heart Fail."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/ejhf.2533","article-title":"Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis","volume":"24","author":"Porcari","year":"2022","journal-title":"Eur J Heart Fail."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1002\/ejhf.2616","article-title":"Value of the HFA-PEFF and H2 FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis","volume":"24","author":"Tomasoni","year":"2022","journal-title":"Eur J Heart Fail."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1093\/eurheartj\/ehz298","article-title":"Treatment of cardiac transthyretin amyloidosis: an update","volume":"40","author":"Emdin","year":"2019","journal-title":"Eur Heart J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA."},{"key":"B29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo Gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejim.2020.09.025","article-title":"Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery","volume":"82","author":"Porcari","year":"2020","journal-title":"Eur J Intern Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1232212\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:59:23Z","timestamp":1689641963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1232212\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":32,"alternative-id":["10.3389\/fmed.2023.1232212"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1232212","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2023,7,17]]},"article-number":"1232212"}}